期刊论文

【摘要】

The rationale for specific pharmacologic therapy in nonalcoholic steatohepatitis (NASH) is determined by the potential for disease progression and the difficulties, in many patients, of successfully implementing diet and lifestyle changes over the long term. Owing to their ability to correct insulin resistance, insulin-sensitizing agents are attractive candidates for the treatment of NASH. In this review we provide an insight into the mechanism of action, therapeutic efficacy and safety issues regarding the use of glitazones in NASH.

【授权许可】

Unknown
© The Author(s), 2011. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav

【预览】

附件列表
Files	Size	Format	View
RO202609290007298ZK.pdf	137KB	PDF	download
Table 3	52KB	Table	download
Table 2.	146KB	Table	download

【参考文献】

[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]
[52]

Therapeutic Advances in Gastroenterology	卷:4
Glitazones for human nonalcoholic steatohepatitis
Reviews
Raluca Pais¹ Ioana Moraru¹
[1] Université Pierre et Marie Curie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Paris, France
关键词: nonalcoholic steatohepatitis; steatosis; fibrosis; insulin resistance; glitazones; insulin sensitizing drugs;
DOI : 10.1177/1756283X11409793
来源: Sage Journals
PDF


	文献评价指标
	下载次数：0次	浏览次数：0次

【 摘 要 】

【 授权许可】

【 预 览 】

【 参考文献 】

【摘要】

【授权许可】

【预览】

【参考文献】